PeerView Clinical Pharmacology CME/CNE/CPE Video - Steven E. Carsons, MD - Addressing Unmet Needs in the Treatment of Primary Sjögren's Syndrome: Expert Insight on the Therapeutic Potential for CD40 Pathway Blockade

Steven E. Carsons, MD - Addressing Unmet Needs in the Treatment of Primary Sjögren's Syndrome: Expert Insight on the Therapeutic Potential for CD40 Pathway Blockade

12/21/21 • 33 min

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/FFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Sjögren’s Syndrome reviews current concepts in the pathophysiology of pSS, and discusses the obstacles faced in recent clinical trials and how new approaches may overcome these obstacles in the future. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with primary Sjögren’s Syndrome, Describe key pathways involved in the pathology of primary Sjögren’s Syndrome and implications for treatment, Evaluate recent clinical trial data related to emerging treatment options for primary Sjögren’s Syndrome, Identify patients who might derive benefit from novel therapeutic options for primary Sjögren’s Syndrome.

Previous Episode

undefined - Joyce O’Shaughnessy, MD - Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors

Joyce O’Shaughnessy, MD - Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors

Go online to PeerView.com/HYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Orally bioavailable CDK4 and 6 inhibitors have become established standard-of-care options in HR+/HER2- metastatic breast cancer, and these agents are now expected to have a major impact in early breast cancer (EBC). CDK4 and 6 inhibition has recently shown significant benefit as adjuvant therapy in patients at high risk of early recurrence, but other studies in the adjuvant and neoadjuvant settings are under way as well. How should these advances be transitioned to the clinic based on the accumulating supportive evidence? How can surgeons and oncologists work together to ensure proper risk assessment and treatment planning to improve outcomes in patients with HR+/HER2- EBC? This PeerView Virtual Workshop provides pertinent updates on the most recent research and available evidence on CDK4 and 6 inhibition in HR+/HER2- EBC, as well as practical, case-based guidance on the application of these agents using individualized treatment plans and effective multidisciplinary collaboration. Upon completion of this CE activity, participants will be able to: Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence, Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 & 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease, Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Next Episode

undefined - Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.